Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP6V1B1 | P15313 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581522 | 0.86 | HTR4 (0.39) | ATP6V1B1HTR4 | |
| SCHEMBL6439063 | 0.84 | HDAC6 (0.49) | ATP6V1B1HDAC4HDAC6EZH2 | |
| SCHEMBL6439903 | 0.82 | MEN1 (0.41) | ATP6V1B1USP30HDAC4HDAC6EZH2 | |
| SCHEMBL6438031 | 0.76 | PRKAG1 (0.47) | — | |
| SCHEMBL6580792 | 0.75 | ATP6V1B1 (0.50) | ATP6V1B1HTR4HSD17B10EZH2 | |
| SCHEMBL6582454 | 0.75 | EZH2 (0.39) | ATP6V1B1HDAC4HDAC6EZH2 | |
| SCHEMBL5651116 | 0.74 | EGFR (0.40) | EGFRHTR4 | |
| SCHEMBL6583037 | 0.74 | ATP6V1B1 (0.43) | ATP6V1B1HSD17B10EZH2 | |
| SCHEMBL6582746 | 0.72 | MCHR1 (0.54) | ATP6V1B1HTR4 | |
| SCHEMBL6440355 | 0.72 | KCNQ2 (0.43) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042316-B1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2005-02-09 | — | — | EP | claimed |
| US-6506758-B2 | 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethyl -piperidin-4-yl)benzamide, for example; selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity | SMITHKLINE BEECHAM LABORATOIRES PHARMCEUTIQUES (FR) | 2003-01-14 | — | — | US | claimed |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES | 2002-07-25 | — | — | US | claimed |
| EP-1042316-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 2000-10-11 | — | — | EP | claimed |
| WO-1999033822-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1999-07-08 | — | — | WO | claimed |
| EP-1042316-B1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2005-02-09 | — | — | EP | disclosed |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| US-6506758-B2 | 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethyl -piperidin-4-yl)benzamide, for example; selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity | SMITHKLINE BEECHAM LABORATOIRES PHARMCEUTIQUES (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES | 2002-07-25 | — | — | US | disclosed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SOST, NR3C2, EBP | ATP6V1B1 3106/4885USP30 3647/4885EGFR 878/4885 |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | ATP6V1B1 401/4885USP30 4049/4885EGFR 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.